Andrew R. Jordan - 06 Jan 2023 Form 4 Insider Report for IDERA PHARMACEUTICALS, INC.

Role
CHIEF STRATEGY OFFICER
Signature
/s/ John J. Kirby, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
06 Jan 2023
Net transactions value
-$52,490
Form type
4
Filing time
10 Jan 2023, 20:19:02 UTC
Previous filing
30 Sep 2022
Next filing
19 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDRA Common Stock Award $0 +261,718 +40% $0.000000 913,082 06 Jan 2023 Direct F1
transaction IDRA Common Stock Tax liability $52,490 -73,940 -8.1% $0.7099 839,142 06 Jan 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock granted under the Idera Pharmaceuticals, Inc. 2013 Stock Incentive Plan, as amended and restated. The shares were granted pursuant to that certain Employment Continuation and Retention Bonus Letter Agreement, dated as of September 28, 2022, between the Issuer and Reporting Person.
F2 Represents the number of shares withheld by Issuer to cover tax obligations in connection with the grant of the shares of common stock.